分红方面，爱朋医疗A股上市后累计派现1.13亿元。近三年，累计派现1638.62万元。 爱朋医疗今年以来股价涨51.84%，近5个交易日跌13.16%，近20日跌11.04%，近60日跌24.70%。 11月19日，爱朋医疗盘中下跌2.09%，截至11:29，报26.67元/股，成交5657.84万元，换手率2.39%，总 市值33.62亿元。 爱朋医疗所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：机器人概念、人工智 能、人脑工程（脑机接口）、专精特新、医用耗材等。 资金流向方面，主力资金净流出639.98万元，大单买入643.01万元，占比11.36%，卖出1282.99万元，占 比22.68%。 截至9月30日，爱朋医疗股东户数2.21万，较上期减少31.76%；人均流通股3972股，较上期增加 46.51%。2025年1月-9月，爱朋医疗实现营业收入2.52亿元，同比减少8.41%；归母净利润-1148.42万 元，同比减少401.64%。 今年以来爱朋医疗已经6次登上龙虎榜，最近一次登上龙虎榜为8月8日，当日龙虎榜净买入1192.43万 元；买入总计7835.89万元 ，占总成交额比 ...

Core Insights - AtriCure reported $134.27 million in revenue for Q3 2025, a 15.8% year-over-year increase, with an EPS of -$0.01 compared to -$0.17 a year ago, indicating significant improvement in earnings performance [1] - The revenue exceeded the Zacks Consensus Estimate by 2.09%, while the EPS surprise was 90.91% above the consensus estimate [1] Revenue Performance - United States Revenue for Pain Management reached $20.84 million, surpassing the average estimate of $20.59 million, reflecting a year-over-year increase of 27.7% [4] - International Revenue for Pain Management was $2.08 million, below the average estimate of $2.77 million, but still showing a year-over-year increase of 30.8% [4] - Total Ablation Revenue in the United States was $63.86 million, exceeding the $63.41 million estimate, with a year-over-year change of 10.04% [4] - International Total Ablation Revenue was reported at $14.79 million, above the $14.54 million estimate, marking a 24.52% year-over-year increase [4] - Overall United States Revenue totaled $109.31 million, surpassing the $106.47 million estimate, with a year-over-year increase of 14.5% [4] Segment Performance - United States Revenue for Open Ablation was $35.59 million, exceeding the average estimate of $34.88 million, reflecting a year-over-year increase of 16.3% [4] - International Revenue for Open Ablation reached $10.85 million, above the $9.73 million estimate, with a year-over-year increase of 26.1% [4] - United States Revenue for Minimally Invasive Ablation was $7.43 million, below the average estimate of $7.94 million, showing a significant year-over-year decline of 33.2% [4] - International Revenue for Minimally Invasive Ablation was $1.86 million, slightly below the $2.04 million estimate, but showing a year-over-year increase of 10.8% [4] - United States Revenue for Appendage Management was $45.45 million, exceeding the average estimate of $43.06 million, with a year-over-year increase of 21.5% [4] - International Total Revenue was reported at $24.96 million, slightly below the $25.12 million estimate, but reflecting a year-over-year increase of 22% [4] Stock Performance - AtriCure's shares have returned -4.02% over the past month, contrasting with the Zacks S&P 500 composite's +0.95% change, indicating underperformance relative to the broader market [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential for performance in line with the broader market in the near term [3]

Group 1 - The core viewpoint of the news is that Aipeng Medical has seen a stock price increase of 5.07%, reaching 30.45 CNY per share, with a trading volume of 240 million CNY and a turnover rate of 9.16%, resulting in a total market capitalization of 3.838 billion CNY [1] - Aipeng Medical, established on October 30, 2001, and listed on December 13, 2018, specializes in the development, production, and sales of medical devices in the fields of pain management and nasal care [1] - The company's main business revenue composition includes pain management products at 59.73%, nasal and upper airway products at 29.40%, and other products at 10.87% [1] Group 2 - From the perspective of fund holdings, Beixin Ruifeng Fund has one fund heavily invested in Aipeng Medical, specifically the Beixin Ruifeng Health Life Theme Flexible Allocation Fund (001056), which holds 120,000 shares, accounting for 4.43% of the fund's net value, ranking as the tenth largest holding [2] - The Beixin Ruifeng Health Life Theme Flexible Allocation Fund (001056) was established on March 27, 2015, with a latest scale of 89.3779 million CNY, and has achieved a year-to-date return of 29.73%, ranking 2969 out of 8161 in its category [2] - The fund has a one-year return of 32.8%, ranking 2786 out of 8021, and a cumulative return since inception of 23.5% [2]

Group 1 - The core viewpoint of the news is the performance and market position of Aipeng Medical, which saw a stock price increase of 5.53% to 29.75 CNY per share, with a total market capitalization of 3.75 billion CNY [1] - Aipeng Medical specializes in the development, production, and sales of medical devices in the pain management and nasal care sectors, with revenue composition being 59.73% from pain management products, 29.40% from nasal and upper airway products, and 10.87% from other sources [1] - The company is located in the Jiangsu province and was established on October 30, 2001, with its listing date on December 13, 2018 [1] Group 2 - The North Trust Ruifeng Fund holds a significant position in Aipeng Medical, with its health lifestyle theme flexible allocation fund (001056) owning 120,000 shares, accounting for 4.43% of the fund's net value, ranking as the tenth largest holding [2] - The fund has achieved a year-to-date return of 27.84% and a one-year return of 60.98%, with a total fund size of 89.38 million CNY [2] - The fund manager, Pang Wenjie, has been in position for over 5 years, with the best fund return during his tenure being 44.46% [3]

Core Viewpoint - Aipeng Medical's stock has experienced significant fluctuations, with a year-to-date increase of 66.92% but a recent decline in the last five and twenty trading days [2] Group 1: Stock Performance - As of September 19, Aipeng Medical's stock price was 29.32 CNY per share, with a market capitalization of 3.696 billion CNY [1] - The stock has seen a decline of 5.08% over the last five trading days and 13.92% over the last twenty trading days [2] - Year-to-date, the stock has been on the龙虎榜 (top trading list) six times, with the most recent net buy of 11.9243 million CNY on August 8 [2] Group 2: Financial Performance - For the first half of 2025, Aipeng Medical reported a revenue of 159 million CNY, a year-on-year decrease of 11.31%, and a net profit of -19.3791 million CNY, a decrease of 317.90% [2] - Cumulative cash dividends since the A-share listing amount to 113 million CNY, with 16.3862 million CNY distributed over the last three years [3] Group 3: Company Overview - Aipeng Medical, established on October 30, 2001, specializes in the development, production, and sales of medical devices in pain management and nasal care [2] - The company's revenue composition includes 59.73% from pain management products, 29.40% from nasal and upper airway products, and 10.87% from other sources [2] - As of June 30, 2025, the number of shareholders increased by 57.18% to 32,400, while the average circulating shares per person decreased by 36.33% to 2,711 shares [2]

Company Overview - Aipeng Medical experienced a decline of 5.03% on September 18, with a stock price of 29.65 yuan per share, a trading volume of 230 million yuan, a turnover rate of 8.57%, and a total market capitalization of 3.737 billion yuan [1] Business Operations - Aipeng Medical, established on October 30, 2001, and listed on December 13, 2018, is located in the Jiangsu Province. The company specializes in the research, development, production, and sales of medical devices in the fields of pain management and nasal care [1] - The revenue composition of Aipeng Medical includes: 59.73% from pain management products, 29.40% from nasal and upper airway products, and 10.87% from other sources [1] Fund Holdings - According to data, Beixin Ruifeng Fund has one fund heavily invested in Aipeng Medical. The Beixin Ruifeng Health Life Theme Flexible Allocation Fund (001056) held 120,000 shares, accounting for 4.43% of the fund's net value, ranking as the tenth largest holding [2] - The fund has reported a floating loss of approximately 188,400 yuan as of the latest data [2] Fund Performance - The Beixin Ruifeng Health Life Theme Flexible Allocation Fund (001056) was established on March 27, 2015, with a latest scale of 89.3779 million yuan. Year-to-date, it has achieved a return of 35.19%, ranking 2286 out of 8172 in its category. Over the past year, it has returned 70.92%, ranking 1705 out of 7980, and since inception, it has returned 28.7% [2]

Core Viewpoint - Aipeng Medical's stock price has shown significant volatility, with a year-to-date increase of 77.97% but a recent decline in the last 20 days by 7.71% [2] Group 1: Stock Performance - On September 17, Aipeng Medical's stock fell by 2.04%, trading at 31.26 CNY per share with a total transaction volume of 1.49 billion CNY and a market capitalization of 39.40 billion CNY [1] - The stock has experienced a 3.61% increase over the last five trading days and a 5.50% increase over the last 60 days [2] Group 2: Financial Performance - For the first half of 2025, Aipeng Medical reported a revenue of 1.59 billion CNY, a year-on-year decrease of 11.31%, and a net profit attributable to shareholders of -19.38 million CNY, a decrease of 317.90% [2] - Cumulative cash dividends since the company's A-share listing amount to 113 million CNY, with 16.39 million CNY distributed over the past three years [3] Group 3: Shareholder and Market Activity - As of June 30, 2025, the number of shareholders increased by 57.18% to 32,400, while the average circulating shares per person decreased by 36.33% to 2,711 shares [2] - Aipeng Medical has appeared on the trading leaderboard six times this year, with the most recent instance on August 8, where net purchases amounted to 11.92 million CNY [2]

Company Overview - Aipeng Medical, established on October 30, 2001, and listed on December 13, 2018, specializes in the development, production, and sales of medical devices in pain management and nasal care [1][2] - The company's revenue composition includes 59.73% from pain management products, 29.40% from nasal and upper airway products, and 10.87% from other sources [1] Stock Performance - As of August 29, Aipeng Medical's stock price increased by 2.15% to 33.80 CNY per share, with a total market capitalization of 4.26 billion CNY [1] - Year-to-date, the stock has risen by 92.43%, with a recent decline of 0.76% over the last five trading days, a 9.88% increase over the last 20 days, and a 27.31% increase over the last 60 days [1] Financial Performance - For the first half of 2025, Aipeng Medical reported a revenue of 159 million CNY, a year-on-year decrease of 11.31%, and a net profit attributable to shareholders of -19.38 million CNY, a decrease of 317.90% [2] - The company has distributed a total of 113 million CNY in dividends since its A-share listing, with 16.36 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, Aipeng Medical had 32,400 shareholders, an increase of 57.18% from the previous period, with an average of 2,711 circulating shares per shareholder, a decrease of 36.33% [2] - Notably, the fund "Huaxia Innovation Future Mixed (LOF)" has exited the list of the top ten circulating shareholders [3]

Group 1 - The core viewpoint of the news is that Aipeng Medical experienced a decline in stock price, dropping by 5.02% to 34.47 CNY per share, with a trading volume of 419 million CNY and a turnover rate of 13.59%, resulting in a total market capitalization of 4.345 billion CNY [1] - Aipeng Medical, established on October 30, 2001, and listed on December 13, 2018, specializes in the development, production, and sales of medical devices in the fields of pain management and nasal care [1] - The company's main business revenue composition includes pain management products at 61.52%, nasal and upper airway products at 30.55%, other products at 7.55%, and other businesses at 0.37% [1] Group 2 - According to data from the top ten heavy stocks of funds, Beixin Ruifeng Fund holds a significant position in Aipeng Medical, with its health living theme flexible allocation fund (001056) holding 120,000 shares, accounting for 4.43% of the fund's net value, ranking as the tenth largest heavy stock [2] - The fund, established on March 27, 2015, has a latest scale of 89.3779 million CNY, with a year-to-date return of 40.86%, ranking 1022 out of 8194 in its category, and a one-year return of 81.22%, ranking 687 out of 7962 [2] - The fund manager, Pang Wenjie, has been in position for 5 years and 88 days, with the fund's total asset scale at 17 million CNY, achieving a best return of 44.46% and a worst return of -44.25% during his tenure [3]

Group 1 - The core viewpoint of the news is that Aipeng Medical's stock has experienced a decline of 5.02%, with a current price of 34.47 CNY per share and a total market capitalization of 4.345 billion CNY [1] - Aipeng Medical, established on October 30, 2001, specializes in the development, production, and sales of medical devices in the pain management and nasal care sectors [1] - The company's revenue composition includes 61.52% from pain management products, 30.55% from nasal and upper airway products, 7.55% from other products, and 0.37% from other businesses [1] Group 2 - Among the top circulating shareholders of Aipeng Medical, Huaxia Fund's Huaxia Innovation Future Mixed Fund (LOF) has recently entered the top ten, holding 589,700 shares, which is 0.67% of the circulating shares [2] - The Huaxia Innovation Future Mixed Fund (LOF) was established on October 13, 2020, with a latest scale of 2.265 billion CNY and has achieved a year-to-date return of 33.22% [2] - The fund's performance over the past year shows a return of 57.97%, ranking 1810 out of 7962 in its category, while it has experienced a cumulative loss of 31.38% since inception [2]